Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun;5(3):683-98.
doi: 10.2147/tcrm.s4975. Epub 2009 Aug 20.

Incretin-based therapies: new treatments for type 2 diabetes in the new millennium

Joan Khoo  1 , Christopher K Rayner, Karen L Jones, Michael Horowitz
Affiliations

Incretin-based therapies: new treatments for type 2 diabetes in the new millennium

Joan Khoo et al. Ther Clin Risk Manag. 2009 Jun.

Abstract

The advent of 'incretin-based therapies' - GLP-1 agonists and dipeptidyl-peptidase-4 inhibitors - which result in improvements in glycemic control comparable to those with existing oral hypoglycemic agents, and potentially improve cardiovascular and pancreatic beta-cell function, represents a major therapeutic advance in the management of type 2 diabetes. Gastrointestinal adverse effects occur commonly with GLP-1 agonists, and rarely with DPP-4 inhibitors, but are dose-dependent and usually transient. The low risk of hypoglycemia, and beneficial or neutral effects on body weight, render GLP-1 agonists and DPP-4 inhibitors suitable alternatives to insulin secretagogues and insulin in overweight and elderly patients. Incretin-based therapies also improve quality of life in patients with type 2 diabetes, and may be cost-effective in the long term.

Keywords: DPP-4; GLP-1; incretin; therapy; type 2 diabetes.

PubMed Disclaimer

References

    1. IDF Clinical Guidelines Task Force Global guideline for type 2 diabetes: recommendations for standard, comprehensive and minimal care. Diabet Med. 2006;23:579–593. - PubMed
    1. UKPDS Group Intensive blood-glucose control with sulphonylureas or inslin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853. - PubMed
    1. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on Optimal Diabetes Control in type 2 diabetic patients. Diabetes Care. 2000;23:B21–B29. - PubMed
    1. Nathan DM, Buse JB, Davidson MB, et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203. - PMC - PubMed
    1. Currie CJ, Poole CD, Gale EA.The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 2009July2 (Epub ahead of print) - PubMed